Clear Search

Showing 1 result for “Thielen R”.

September 2023

実臨床における1年間の治療アドヒアランスおよび治療継続: Upadacitinib, Adalimumab, Baricitinib, Tofacitinibのレトロスペクティブデータ

Adv Ther. 2023;40(10):4493–4503 doi 10.1007/s12325-023-02619-6

This study by Bergman, et al. showed that RA patients are significantly more likely to adhere to upadacitinib within the first 12 months of prescription versus adalimumab, baricitinib, and tofacitinib. There was also a significantly lower risk of discontinuation for upadacitinib versus the other treatment prescriptions.